Fresh analysis reveals that people who stop using new slimming jabs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional diet and exercise plans.
Research printed in a leading health publication demonstrates that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals purchasing these treatments should be informed of the danger of rapid rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to starting mass within about a year and a half.
Comparing Therapies
The research, which examined dozens of studies involving thousands of patients, compared the results of the injectable medications with older methods.
Scientists point out that individuals who shed pounds through dieting typically have a slower creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Experts suggest the mechanism of the drugs is key to understanding the accelerated regain.
The injections mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels several times higher than normal might result in the body to produce less of its own natural hormone, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement leads to hunger is unsuppressed, making binge eating far more likely."
An Ongoing Condition?
The NHS recommend the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Professionals contend that, considering the likelihood of relapse, the treatment might need to be ongoing.
This view is supported by drug manufacturers, who state that the findings "underscore the chronic nature of obesity," comparing it to managing conditions like hypertension.
Patient Experiences
People who have discontinued the medication describe a powerful return of cravings.
"I experienced a switch that goes on and you're instantly extremely hungry," said a patient.
The struggle is compounded if users have not developed sustainable dietary or behavioural modifications during treatment.
Growing Use
Figures show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is greater among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while these medications are potent agents for weight loss, they are not a permanent cure and maintained weight loss hinges on combined lifestyle changes.
